Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy

被引:1
|
作者
Erlandsson, Ann [1 ,2 ]
Lundholm, Marie [3 ]
Watz, Johan [2 ]
Bergh, Anders [3 ]
Petrova, Elitsa [4 ]
Alamdari, Farhood [5 ]
Helleday, Thomas [6 ]
Davidsson, Sabina [1 ]
Andren, Ove [1 ]
Tarish, Firas [6 ]
机构
[1] Orebro Univ, Fac Med & Hlth, Dept Urol, Orebro, Sweden
[2] Karlstad Univ, Dept Environm & Life Sci Biol, S-65188 Karlstad, Sweden
[3] Umea Univ, Dept Med Biosci, Umea, Sweden
[4] Cent Hosp Karlstad, Dept Clin Pathol & Cytol, Karlstad, Sweden
[5] Vastmanlands Hosp, Dept Urol, Vasteras, Sweden
[6] Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, Stockholm, Sweden
关键词
Prostate cancer; androgen deprivation therapy; radiotherapy; immune cells; multiplex IHC; ANTITUMOR EFFICACY; EXPRESSION;
D O I
10.1177/03946320231158025
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
ObjectivesAndrogen deprivation therapy (ADT) has long been a cornerstone in treatment of advanced prostate cancer (PCa), and is known to improve the results of radiotherapy (RT) for high-risk disease. The purpose of our study was to use a multiplexed immunohistochemical (mIHC) approach to investigate the infiltration of immune cells in PCa tissue after eight weeks of ADT and/or RT with 10 Gy.MethodsFrom a cohort of 48 patients divided into two treatment arms, we obtained biopsies before and after treatment and used a mIHC method with multispectral imaging to analyze the infiltration of immune cells in tumor stroma and tumor epithelium, focusing on areas with high infiltration.ResultsTumor stroma showed a significantly higher infiltration of immune cells compared to tumor epithelium. The most prominent immune cells were CD20(+) B-lymphocytes, followed by CD68(+) macrophages, CD8(+) cytotoxic T-cells, FOXP3(+) regulatory T-cells (Tregs), and T-bet(+) Th1-cells. Neoadjuvant ADT followed by RT significantly increased the infiltration of all five immune cells. Numbers of Th1-cells and Tregs significantly increased after single treatment with ADT or RT. In addition, ADT alone increased the number of cytotoxic T-cells and RT increased the number of B-cells.ConclusionsNeoadjuvant ADT in combination with RT results in a higher inflammatory response compared to RT or ADT alone. The mIHC method may be a useful tool for investigating infiltrating immune cells in PCa biopsies to understand how immunotherapeutic approaches can be combined with current PCa therapies.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Decreased testosterone recovery after androgen deprivation therapy for prostate cancer
    Long, Margaret E.
    Vitale, Andrew M.
    Mott, Sarah L.
    Tracy, Chad
    Garje, Rohan
    Zakharia, Yousef
    Brown, James A.
    CANADIAN JOURNAL OF UROLOGY, 2021, 28 (04) : 10738 - 10742
  • [32] Prolonged hypogonadism after cessation of androgen deprivation therapy for prostate cancer
    Rodriguez-Rubio Cortadellas, Federico I.
    Jimenez Romero, Miguel E.
    Gonzalez Moreno, Delfin
    Novalbos Ruiz, Jose P.
    Garrido Insua, Sofia
    ACTAS UROLOGICAS ESPANOLAS, 2009, 33 (07): : 747 - 754
  • [33] Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies
    Zapatero, A.
    Gonzalez San Segundo, C.
    Boladeras, A.
    Gomez Caamano, A.
    Lopez Torrecilla, J.
    Maldonado, X.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (03) : 223 - 229
  • [34] Androgen and prostate cancer: the role of primary androgen deprivation therapy in localized prostate cancer
    Namiki, Mikio
    Kitagawa, Yasuhide
    Mizokami, Atsushi
    Koh, Eitetsu
    JOURNAL OF MENS HEALTH, 2008, 5 (04) : 333 - 341
  • [35] Androgen deprivation plus conformal radiotherapy for prostate cancer: effects on morbidity
    Dearnaley, D
    NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (01): : 18 - 18
  • [36] Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies
    A. Zapatero
    C. González San Segundo
    A. Boladeras
    A. Gómez Caamaño
    J. López Torrecilla
    X. Maldonado
    Clinical and Translational Oncology, 2015, 17 : 223 - 229
  • [37] Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy
    Shiota, Masaki
    Yokomizo, Akira
    Takeuchi, Ario
    Imada, Kenjiro
    Kiyoshima, Keijiro
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Ohga, Saiji
    Nakamura, Katsumasa
    Honda, Hiroshi
    Naito, Seiji
    ONCOTARGET, 2015, 6 (16) : 14710 - 14719
  • [38] Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A systematic review and meta-analysis
    Chen, Jiuzhou
    Yuan, Yan
    Fang, Miao
    Zhu, Youqi
    Sun, Xueqing
    Lou, Yufei
    Xin, Yong
    Zhou, Fengjuan
    FRONTIERS IN ENDOCRINOLOGY, 2023, 13
  • [39] Neoadjuvant androgen deprivation for prostate volume reduction: The optimal duration in prostate cancer radiotherapy
    Langenhuijsen, Johan F.
    van Lin, Emile N.
    Hoffmann, Aswin. L.
    Spitters-Post, Ilse
    Witjes, J. Alfred
    Kaanders, Johannes H.
    Mulders, Peter F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (01) : 52 - 57
  • [40] Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy
    Filon, Mikolaj J.
    Gillette, Amani A.
    Yang, Bing
    Khemees, Tariq A.
    Skala, Melissa C.
    Jarrard, David F.
    PROSTATE, 2022, 82 (16) : 1547 - 1557